News
2h
Zacks Investment Research on MSNExelixis Gains 15.6% YTD: How Should You Play the Stock?
Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...
During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...
With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...
Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...
In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...
PureTech Health has launched a subsidiary company – Celea Therapeutics – with the task of taking an experimental drug for ...
The recent data readout from studies on zanzalintinib has been positive. In June 2025, EXEL announced positive top-line results from the late-stage STELLAR-303 study. This phase III study is a global, ...
In this Phase III trial, the Padcev-Keytruda combination used as both neoadjuvant and adjuvant therapy significantly improved event-free and overall survival, as well as pathologic complete response, ...
Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...
In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.
1d
Asianet Newsable on MSNPfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5: Retail Says Stock Is Undervalued
According to a Bloomberg report, Pfizer has requested that the approval stay in place through the coming fall season.
US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results